Currently, anti-obesity drugs have been focused on neuroendocrine mechanisms, including sympathomimetic drugs, 5-HT2c serotonin agonists, opioid receptor antagonist/dopamine, noradrenaline reuptake inhibitor, pancreatic lipase inhibitor, and incretin co-agonists (12), while junction transformation of lacteals in obesity may be a promising target for obesity treatment, appealing to scientists and clinicians (13). This evidence concerns the gene PNLIP and obesity due to melanocortin 4 receptor deficiency.